Oneness Biotech Co., Ltd. (4743) Stock Price & Analysis
4743 Stock Chart & Stats
- Day’s Range
- TWD 40.10 - TWD 45.25
- 52-Week Range
- TWD 40.10 - TWD 76.70
- Previous Close
- TWD 44.30
- Volume
- N/A
- Average Volume (3M)
- 1.30M
- Market Cap
- TWD 21.56B
- Enterprise Value
- TWD 20.17B
- Total Cash (Recent Filing)
- TWD 5.43B
- Total Debt (Recent Filing)
- TWD 352.21M
- Price to Earnings (P/E)
- 361.0
- Beta
- 0.63
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 16, 2023
- Dividend Yield
- N/A
4743 FAQ
What was Oneness Biotech Co., Ltd.’s price range in the past 12 months?
What is Oneness Biotech Co., Ltd.’s market cap?
When is Oneness Biotech Co., Ltd.’s upcoming earnings report date?
How were Oneness Biotech Co., Ltd.’s earnings last quarter?
Is Oneness Biotech Co., Ltd. overvalued?
Does Oneness Biotech Co., Ltd. pay dividends?
What is Oneness Biotech Co., Ltd.’s EPS estimate?
How many shares outstanding does Oneness Biotech Co., Ltd. have?
What happened to Oneness Biotech Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oneness Biotech Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Oneness Biotech Co., Ltd.
Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related merchandise. The company's operations are divided into its New Drug Research and Development segment and its Agricultural Products Cultivation segment. Its advanced therapeutic candidate, ON101, is currently undergoing Phase III clinical trials for the treatment of chronic diabetic foot ulcers. Additionally, OB318, an experimental anti-cancer drug, is progressing through Phase I clinical evaluation. The company's development pipeline further includes FB704A, which has successfully concluded its Phase I clinical trial for addressing rheumatoid arthritis and systemic sclerosis. Furthermore, FB825 is currently in Phase II clinical trials, targeting conditions like atopic dermatitis, various allergic diseases, and asthma. In its earlier stages, FB918, a human monoclonal antibody aimed at allergic asthma, is undergoing pre-clinical development. Beyond its pharmaceutical endeavors, Oneness Biotech also oversees agricultural cultivation and trading activities, encompassing the distribution of farm produce. The company was established and began operations in 2008.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Shuling Cheng
- Employees
- 180
- Website
- www.onenessbio.com.tw
- Address
- No. 66, Zhonzheng W. Rd, Taipei, TPE, 100, TW
Oneness Biotech Co., Ltd. (4743) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |

